Healthcare Sector Stocks for Investors: Raptor Pharmaceutical Corp. (RPTP), Celator Pharmaceuticals Inc (CPXX)

0
29

Raptor Pharmaceutical Corp. (NASDAQ:RPTP)

Stock’s Trading Stats:

Raptor Pharmaceutical Corp. (NASDAQ:RPTP) surged 8.05% friday and closed at $5.64. The company’s market capitalization is at $519.46 Million with an average trading volume of 1.18 Million. The total number of Outstanding Shares Held by the company are 85.24 Million.

Recent Press Release:

Raptor Pharmaceuticals Corp. (RPTP) on April 11, 2016 declared its first commercial sale of QUINSAIR™ (levofloxacin inhalation solution) in Germany and Denmark. QUINSAIR is approved in the European Union (EU) and Canada for the administration of chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with cystic fibrosis (CF). It is the first fluoroquinolone to be approved as an inhaled therapy for a pulmonary disease. The treatment is administered twice-daily, stored at room temperature and has a short administration time. Launches in additional EU countries and Canada are anticipated for QUINSAIR in 2016.

Dave Happel, Raptor’s Chief Commercial Officer, said, “Raptor is excited to offer a new, first-in-class inhaled antibiotic treatment option for the many patients and families living with cystic fibrosis and battling chronic bacterial lung infections. We are startning the European launch of QUINSAIR in Germany and Denmark, and continue to pursue approval of QUINSAIR for CF patients in the United States.”

Happel added, “We are confident that QUINSAIR will be an important growth driver for Raptor. We expect QUINSAIR to enhance our revenue base and enhance our long-term growth profile while leveraging our commercial and development expertise and our existing global infrastructure.”

Celator Pharmaceuticals Inc (NASDAQ:CPXX)

Stock’s Trading Stats:

Celator Pharmaceuticals Inc (NASDAQ:CPXX)  closed at $15.05 friday by showing an increase of 7.50%. The total number of outstanding shares held by the company are 36.39 Million with the total market capitalization of $653.40 Million. The number of shares traded on the last trading session are 3.54Million.

Recent Press Release:

Celator Pharmaceuticals, Inc. (CPXX) a clinical stage biopharmaceutical company, develops therapies to treat cancer. Its proprietary drug ratio technology platform, CombiPlex, enables the rational design and rapid evaluation of optimized combinations incorporating traditional chemotherapies, in addition to molecularly targeted agents to deliver improved anti-cancer activity. The company’s product pipeline comprises CPX-351, a liposomal formulation of cytarabine:daunorubicin, which is in Phase III study for the treatment of acute myeloid leukemia; and CPX-1, a liposomal formulation of irinotecan:floxuridine that has accomplished Phase II study for the treatment of colorectal cancer. Its preclinical stage product candidate is CPX-8, a hydrophobic docetaxel prodrug nanoparticle formulation for vitro and vivo studies. The company was founded in 1999 and is headquartered in Ewing, New Jersey.